Sanofi Says U.S. Waiting Period for Bioverativ Has Expired
February 23 2018 - 6:44AM
Dow Jones News
By Sonia Amaral Rohter
Sanofi SA (SAN.FR) said on Friday that a U.S. waiting period for
its proposed acquisition of Bioverativ Inc. (BIVV) has expired
without objections.
With the expiration, "the condition to the offer relating to
antitrust approvals has been satisfied," Sanofi said.
The waiting period--a notification program under the U.S.
Hart-Scott-Rodino Antitrust Improvements Act--requires parties to
certain transactions to submit notification to the U.S. Federal
Trade Commission and Department of Justice and wait before the
transaction can be completed.
In January, Sanofi agreed to buy hemophilia drug maker
Bioverativ for approximately $11.6 billion. On Feb. 7, Sanofi
commenced the tender offer, which is scheduled to expire on March
7.
The closing of the offer is still subject to various conditions,
Sanofi said.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
February 23, 2018 06:29 ET (11:29 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Bioverativ Inc. (NASDAQ:BIVV)
Historical Stock Chart
From Nov 2023 to Nov 2024
